Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.52 |
| ▸ | CCND1 | P24385 | 12/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.52 |
| ▸ | CDK2 | P24941 | 9/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.52 |
| ▸ | CCND2 | P30279 | 3/20 | 0.52 |
| ▸ | CCND3 | P30281 | 3/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035418 | 0.91 | CDK4 (0.51) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15041842 | 0.86 | CDK4 (0.51) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15041294 | 0.80 | CDK4 (0.51) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15035472 | 0.77 | CDK4 (0.40) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15041827 | 0.77 | PIK3CD (0.45) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15035447 | 0.77 | — | — | |
| SCHEMBL15035517 | 0.77 | CDK4 (0.50) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15035385 | 0.77 | JAK2 (0.45) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15035587 | 0.76 | JAK3 (0.44) | CDK4CCND1CCNA2CDK2FGFR1 | |
| SCHEMBL15035590 | 0.76 | JAK2 (0.46) | CDK4CCND1CCNA2CDK2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CCNA2 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.